Kite Pharma (KITE): ZUMA-1 Data Creates First Mover Advantage - Stifel
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Stifel analyst, Thomas Shrader, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) after the company released topline data from ZUMA-1 that were considerably better than the standard of care (SOC) with a CR rate of 52% relative to the current SOC (salvage chemotherapies) that would be expected to yield a CR rate of about 8%.
The analyst sees these results as above the expected bar for approval - which physicians familiar with these patients set at about a CR rate of 25%. That being said, it looks like early days in the use of these cells as about of the 25% patients that initially achieve a CR loose their responses within three months (durable-CR rate of 39%). These pseudo-CRs seem to be the low hanging fruit in upcoming efforts to improve the efficacy of KTE-019 and more experienced treaters may be able to close this gap over time. Most importantly, Kite should now enjoy a significant first mover advantage as we expect this learning process to occur in the commercial setting using Kite’s product.
No change to the price target of $74.
Shares of Kite Pharma closed at $54.98 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Stifel Upgrades Abraxas Petroleum (AXAS) to Buy Amid Emerging Delaware Basin Potential
- Skyworks Solutions (SWKS) PT Raised to $105 at Oppenheimer Following 1Q Report
- Generics File Against New Teva Pharma (TEVA) Copaxone 40MG Patent - Evercore ISI
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!